

Product Name	: ZLDI-8
Synonyms	: —
Cat No.	: M22943
CAS Number	: 667880-38-8
Molecular Formula	: C ₂₄ H ₂₃ N ₃ O ₃ S
Formula Weight	: 433.52
Chemical Name	: —
Description	<p>ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein. ZLDI-8; it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins. ZLDI-8 treatment enhanced the susceptibility of HCC cells to a small molecular kinase inhibitor Sorafenib, and chemotherapy agents Etoposide and Paclitaxel. ZLDI-8 treatment enhanced the effect of Sorafenib on inhibiting tumor growth in nude HCC-bearing mice model. In nude HCC-bearing mice model, ZLDI-8 (0.2-2 mg/kg; intraperitoneal injection; every two days; for 20 days; nude mice) treatment enhances the effect of Sorafenib on inhibiting tumor growth.</p>
Pathway	: Others
Target	: Other Targets
Receptor	: ADAM-17
Solubility	: DMSO: 62.5 mg/mL (144.17 mM; Need ultrasonic)
SMILES	: <chem>O=C(C(C(=O)N)=O)C/C2=C(C)N(CCOC3=CC=C(C)C=C3C)C4=C2C=CC=C4)NC1=S</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Zhang Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9(7):743.